Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Schwartz

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
British Journal of Cancer|May 23, 2020
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activityEleftherios Kostaras, Teresa Kaserer, Glorianne Lazaro, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
International Journal of Cancer|February 19, 2016
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyCathy Eng, Alberto Bessudo, Lowell L Hart, et al.
World Journal of Gastroenterology|April 22, 2017
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinomaLorenza Rimassa, Maria Reig, Giovanni Abbadessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
American Heart Journal|March 30, 2013
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) studyAkshay Bagai, Warren J Cantor, Mary Tan, et al.
Investigational New Drugs|October 9, 2014
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsIgor Puzanov, Jeffrey Sosman, Armando Santoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2017
Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophyCaroline J Woo, Verena K Maier, Roshni Davey, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
British Journal of Cancer|May 23, 2020
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activityEleftherios Kostaras, Teresa Kaserer, Glorianne Lazaro, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
International Journal of Cancer|February 19, 2016
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyCathy Eng, Alberto Bessudo, Lowell L Hart, et al.
World Journal of Gastroenterology|April 22, 2017
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinomaLorenza Rimassa, Maria Reig, Giovanni Abbadessa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
American Heart Journal|March 30, 2013
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) studyAkshay Bagai, Warren J Cantor, Mary Tan, et al.
Investigational New Drugs|October 9, 2014
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsIgor Puzanov, Jeffrey Sosman, Armando Santoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2017
Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophyCaroline J Woo, Verena K Maier, Roshni Davey, et al.
Pageof 21